Cancer Stem Cell Populations in Lymphoma in Dogs and Impact of Cytotoxic Chemotherapy

Overview

Journal Vet Comp Oncol

Specialties Oncology
Veterinary Medicine

Date 2018 Sep 22

PMID 30238600

Citations 2

Authors

Genevieve Hartley

Robyn Elmslie

Brent Murphy

Leone Hopkins

Amanda Guth

Steven Dow

Affiliations

Soon will be listed here.

Abstract

Cancer relapse following chemotherapy has been attributed in part to the presence of cancer stem cells (CSC), which drive tumour growth and metastasis and are highly resistant to the effects of cytotoxic chemotherapy. As a result, treatment with cytotoxic chemotherapy selects for drug-resistant CSC populations that eventually drive tumour recurrence. Little is known currently regarding the role of CSC in dogs with lymphoma, nor the impact of chemotherapy on CSC populations. Therefore, we prospectively quantitated CSC populations in dogs with B-cell (BCL) and T-cell lymphoma (TCL), using tumour aspirates and flow cytometric analysis with a panel of CSC markers. In addition, in vitro studies were carried out to determine the impact of chemotherapy resistance on the stem cell phenotype and stem cell properties of lymphoma cells. We found that the percentages of tumour cells expressing CSC markers were significantly increased in dogs with BCL, compared with B cells from normal lymph nodes. Similar findings were observed in dogs with TCL. In vitro studies revealed that lymphoma cells selected for resistance to CHOP chemotherapy had significantly upregulated expression of CSC markers, formed spheroids in culture more readily, and expressed significantly greater aldehyde dehydrogenase activity compared with chemotherapy-sensitive tumour cells. Similar results were observed in tumour samples dogs with relapsed BCL. These findings suggest that cytotoxic chemotherapy can lead to a relative enrichment of tumour cells with CSC properties, which may be associated with lymphoma recurrence.

Citing Articles

CTLA-4 promotes lymphoma progression through tumor stem cell enrichment and immunosuppression.

Chen Y, Li M, Cao J, Cai G, Li X, Liu Y Open Life Sci. 2021; 16(1):909-919.

PMID: 34553071 PMC: 8422981. DOI: 10.1515/biol-2021-0094.

Aggressiveness Potential of Spontaneous Canine Mucosal Melanoma Can Dictate Distinct Cancer Stem Cell Compartment Behaviors in Regard to Their Initial Size and Expansion Abilities.

Touil Y, Segaoula Z, Thuru X, Galiegue-Zouitina S, Tierny D, Quesnel B Stem Cells Dev. 2020; 29(14):919-928.

PMID: 32423311 PMC: 7374591. DOI: 10.1089/scd.2019.0223.

References

Brendel C, Mohr B, Schimmelpfennig C, Muller J, Bornhauser M, Schmidt M . Detection of cytogenetic aberrations both in CD90 (Thy-1)-positive and (Thy-1)-negative stem cell (CD34) subfractions of patients with acute and chronic myeloid leukemias. Leukemia. 1999; 13(11):1770-5. DOI: 10.1038/sj.leu.2401543. View

Blair A, Sutherland H . Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117). Exp Hematol. 2000; 28(6):660-71. DOI: 10.1016/s0301-472x(00)00155-7. View

Jordan C, Upchurch D, Szilvassy S, Guzman M, Howard D, PETTIGREW A . The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000; 14(10):1777-84. DOI: 10.1038/sj.leu.2401903. View

Reya T, Morrison S, Clarke M, Weissman I . Stem cells, cancer, and cancer stem cells. Nature. 2001; 414(6859):105-11. DOI: 10.1038/35102167. View

Garrett L, Thamm D, Chun R, Dudley R, Vail D . Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med. 2002; 16(6):704-9. DOI: 10.1892/0891-6640(2002)016<0704:eoacpw>2.3.co;2. View

Slupphaug G, Kavli B, Krokan H . The interacting pathways for prevention and repair of oxidative DNA damage. Mutat Res. 2003; 531(1-2):231-51. DOI: 10.1016/j.mrfmmm.2003.06.002. View

Buccisano F, Rossi F, Venditti A, Del Poeta G, Cox M, Abbruzzese E . CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias. Br J Haematol. 2004; 125(2):203-12. DOI: 10.1111/j.1365-2141.2004.04883.x. View

Hirschmann-Jax C, Foster A, Wulf G, Nuchtern J, Jax T, Gobel U . A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A. 2004; 101(39):14228-33. PMC: 521140. DOI: 10.1073/pnas.0400067101. View

Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D . Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005; 65(13):5506-11. DOI: 10.1158/0008-5472.CAN-05-0626. View

10.

OHare T, Corbin A, Druker B . Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev. 2005; 16(1):92-9. DOI: 10.1016/j.gde.2005.11.002. View

11.

Simon D, Nolte I, Eberle N, Abbrederis N, Killich M, Hirschberger J . Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol. J Vet Intern Med. 2006; 20(4):948-54. DOI: 10.1892/0891-6640(2006)20[948:todwlu]2.0.co;2. View

12.

Lana S, Plaza S, Hampe K, Burnett R, Avery A . Diagnosis of mediastinal masses in dogs by flow cytometry. J Vet Intern Med. 2006; 20(5):1161-5. DOI: 10.1892/0891-6640(2006)20[1161:dommid]2.0.co;2. View

13.

Li F, Tiede B, Massague J, Kang Y . Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res. 2006; 17(1):3-14. DOI: 10.1038/sj.cr.7310118. View

14.

Allan A, Vantyghem S, Tuck A, Chambers A . Tumor dormancy and cancer stem cells: implications for the biology and treatment of breast cancer metastasis. Breast Dis. 2007; 26:87-98. DOI: 10.3233/bd-2007-26108. View

15.

Kisseberth W, Nadella M, Breen M, Thomas R, Duke S, Murahari S . A novel canine lymphoma cell line: a translational and comparative model for lymphoma research. Leuk Res. 2007; 31(12):1709-20. DOI: 10.1016/j.leukres.2007.04.003. View

16.

Hosen N, Park C, Tatsumi N, Oji Y, Sugiyama H, Gramatzki M . CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci U S A. 2007; 104(26):11008-13. PMC: 1904175. DOI: 10.1073/pnas.0704271104. View

17.

Michael M, Doherty M . Drug metabolism by tumours: its nature, relevance and therapeutic implications. Expert Opin Drug Metab Toxicol. 2007; 3(6):783-803. DOI: 10.1517/17425255.3.6.783. View

18.

Rapp U, Ceteci F, Schreck R . Oncogene-induced plasticity and cancer stem cells. Cell Cycle. 2008; 7(1):45-51. DOI: 10.4161/cc.7.1.5203. View

19.

Yang Z, Ho D, Ng M, Lau C, Yu W, Ngai P . Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 2008; 13(2):153-66. DOI: 10.1016/j.ccr.2008.01.013. View

20.

WILLIAMS M, Avery A, Lana S, Hillers K, Bachand A, Avery P . Canine lymphoproliferative disease characterized by lymphocytosis: immunophenotypic markers of prognosis. J Vet Intern Med. 2008; 22(3):596-601. DOI: 10.1111/j.1939-1676.2008.0041.x. View